NA
Bron
Verkorte titel
Aandoening
follicular lymphoma
Ondersteuning
Onderzoeksproduct en/of interventie
Geen registraties gevonden.
Uitkomstmaten
Primaire uitkomstmaten
Rate of Progression of disease within 24 months from start of second line treatment (second POD24)
Achtergrond van het onderzoek
The optimal treatment strategy in patients with early progressive disease is not well known. In recent years, novel insights into the biology of FL, and especially the role of the microenvironment, have resulted in the development of multiple novel treatment modalities. These new agents may ultimately improve the outlook for patients with FL with an unfavorable course, but for the development of the optimal therapeutic strategy, knowledge on the clinical and biological determinants of early refractory FL is needed.
Doel van het onderzoek
NA
Onderzoeksopzet
NA
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Patients with initial diagnosis of follicular lymphoma, refractory/relapsed/transformed after first line therapy, All stages at the time of relapse, Histological grade 1-3a at the time of initial diagnosis, Age over 18 years, Availability of clinical data, including baseline information, comorbidities, data on disease localization, laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating as requested, Diagnostic material available for review, Written informed consent.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Age < 18 years
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Toelichting
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL7865 |
Ander register | Medical Ethics Review Committee of the Academic Medical Center : W18_431 |